NEW YORK (GenomeWeb News) – Microarray diagnostics firm SQI said Monday that it has raised gross proceeds of C$1.5 million (US$1.3 million) through a non-brokered private placement.

The Toronto-based firm placed almost 3 million units at C$.50 per unit, with each unit consisting of one common share and one common share purchase warrant. Each warrant entitles the holder to purchase one common share at a price of C$.65 for two years from the date of issuance.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.

The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.

CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.

In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.